The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 1 , Pages 85-91 , January 2010

Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

  • Herre J. Reesink, MD, PhD

      Affiliations

    • Department of Pulmonology, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • Sulaiman Surie, MD

      Affiliations

    • Department of Pulmonology, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • Jaap J. Kloek, MD

      Affiliations

    • Department of Cardiothoracic Surgery, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • Hanno L. Tan, MD, PhD

      Affiliations

    • Department of Cardiology, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • Robert Tepaske, MD, PhD

      Affiliations

    • Department of Intensive Care Medicine of the Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • Peter F. Fedullo, MD

      Affiliations

    • Division of Repiratory and Critical Care Medicine, University of California San Diego, San Diego, Calif
    • ,
  • Paul Bresser, MD, PhD

      Affiliations

    • Department of Pulmonology, University of Amsterdam, Amsterdam, The Netherlands
    • Corresponding Author InformationAddress for reprints: P. Bresser, MD, PhD, Academic Medical Center, University of Amsterdam, Department of Pulmonology, F5-144, PO Box 22700, 1100 DE Amsterdam, The Netherlands.

Received 20 October 2008 ,Revised 23 March 2009 ,Accepted 29 March 2009.

References 

  1. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465–1472
  2. Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006;130:172–175
  3. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–2264
  4. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685–692
  5. Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151–158
  6. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23:637–648
  7. Hardziyenka M, Reesink HJ, Bouma BJ, de Bruin-Bon HA, Campian ME, Tanck MW, et al. A novel echocardiographic predictor of in-hospital mortality and mid-term haemodynamic improvement after pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension. Eur Heart J. 2007;28:842–849
  8. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76:1457–1462
  9. Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation. 1990;81:1735–1743
  10. Reesink HJ, Marcus JT, Tulevski II, Jamieson S, Kloek JJ, Vonk Noordegraaf A, et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg. 2007;133:58–64
  11. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23:595–600
  12. Bresser P, Pepke-Zaba J, Jais X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc. 2006;3:594–600
  13. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest. 2003;123:338–343
  14. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034–1036
  15. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J. 2000;15:640–648
  16. Reesink HJ, Meijer RC, Lutter R, Boomsma F, Jansen HM, Kloek JJ, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J. 2006;70:1058–1063
  17. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2599–2603
  18. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2363–2367
  19. Hughes R, George P, Parameshwar J, Cafferty F, Dunning J, Morrell NW, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax. 2005;60:707
  20. Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. Radiology. 1992;182:393–398
  21. Reesink HJ, Tulevski II, Marcus JT, Boomsma F, Kloek JJ, Vonk Noordengraaf A, et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2007;84:537–543
  22. Kim NH. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:584–588
  23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117
  24. Reesink HJ, van der Plas MN, Verhey NE, van Steenwijk RP, Kloek JJ, Bresser P. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2007;133:510–516
  25. Tulevski II, Hirsch A, Sanson BJ, Romkes H, van der Wall EE, van Veldhuisen DJ, et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 2001;86:1193–1196
  26. Jamieson SW, Kapelanski DP. Pulmonary endarterectomy. Curr Probl Surg. 2000;37:165–252
  27. McCulloch KM, Docherty CC, Morecroft I, MacLean MR. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol. 1996;119:1125–1130
  28. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398–405
  29. Hartz RS, Byrne JG, Levitsky S, Park J, Rich S. Predictors of mortality in pulmonary thromboendarterectomy. Ann Thorac Surg. 1996;62:1255–1259
  30. Reichenberger F, Voswinckel R, Enke B, Rutsch M, ElFechtali E, Schmehl T, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2007;30:922–927
  31. Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Tosher M, et al. Acute hemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascul Pharmacol. 2007;46:449–455
  32. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–1123
  33. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903
  34. van der Plas MN, Duffels MG, Ponse D, Mulder BJ, Bresser P. Bosentan in mild pulmonary hypertension. Lancet. 2008;372:1730

 Disclosures: H.J.R. and S.S. received a nonrestricted research grant from Actelion Pharmaceuticals BV, Woerden, The Netherlands.

PII: S0022-5223(09)00513-3

doi: 10.1016/j.jtcvs.2009.03.053

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 1 , Pages 85-91 , January 2010

Article Tools

* Image Usage & Resolution